Candel Therapeutics, Inc. (CADL), headquartered in Needham, Massachusetts, is a leading clinical-stage biotechnology company, committed to developing advanced oncolytic viral immunotherapies for cancer patients. Emphasizing on creating an innovative patient-centric therapeutic approach, the company focuses on comprehending and decoding the complex interactions between tumor cells and the immune system.
Since its inception, Candel has deliberately curated an expansive pipeline of viral immunotherapies in conjunction with its leading-edge Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform. These products target a diverse range of large market, solid tumor indications and have been employed in early and late-stage clinical trials with over 600 patients, showing impressive responses across a broad range of cancers. The most advanced programs are CAN-2409 for newly diagnosed glioblastoma, a type of brain cancer, and CAN-3110 for prostate cancer, both currently in Phase 3 studies.
Candel Therapeutics' immuno-oncology approach uses GMCI™, which involves the delivery of a non-replicating viral vector encoding for the enzyme, herpes simplex virus thymidine kinase. This leads to localized production of the protein, which generates a comprehensive immune response both locally and systemically. This process essentially changes the entire tumor into a vaccine, producing an immune response that can eliminate residual disease and prevent cancer recurrence.
Additionally, Candel Therapeutics' pipeline includes next-generation viral immunotherapies. They are developing these therapies for various types of cancers including pancreatic, lung, and colorectal. These deliver multiple immune-stimulating genes directly into the tumor, aiming to generate a more robust immune response.
As a biotechnology leader, the company has created an expansive intellectual property portfolio providing protection for its GMCI™ platform and product candidates. Candel Therapeutics, Inc. is committed to improving patient outcomes by advancing cutting-edge immunotherapies in oncology, enabling a future where cancer treatments are more efficient, effective, and accessible. Supported by its strong scientific acumen and dedicated team, the company continuously endeavors to expand the horizons of cancer therapeutics.
Overall, Candel Therapeutics, Inc. is a precision medicine-focused entity, at the forefront of exploring and developing innovative technologies to challenge and change the existing paradigms of cancer care. Its dedication to research, testing and therapeutic implementation is not just propelling the company forward, but also contributing to progress in the broader biotech and healthcare sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Candel Therapeutics Inc. (NASDAQ: CADL) and suggests choppy market conditions due to divergent sentiment across various time horizons. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating support and resistance levels. The report highlights an exceptional 68.7:1 risk-reward setup targeting an 18.9% gain versus 0.3% risk.
Candel Therapeutics (CADL) stock rose by 3.9% after BofA upgraded the company's rating to "buy." The article, from MT Newswires, requires a premium subscription to read the full details of the upgrade and associated analysis.
BofA Securities has upgraded Candel Therapeutics (CADL) from Neutral to Buy, setting a new price target of $18. This upgrade led to a rise in Candel Therapeutics' shares, reflecting increased analyst confidence in the biopharmaceutical company. The company is developing off-the-shelf multimodal biological immunotherapies for cancer, with lead product candidates CAN-2409 and CAN-3110.
Bank of America has upgraded Candel Therapeutics (CADL) from Neutral to Buy, setting a new price target of $18. The company currently holds an average rating of Buy among analysts with a mean price target of $21.75. Access to the full MT Newswires article requires a premium subscription.
Candel Therapeutics (CADL) reported widening net losses of US$38.91 million in Q2 2026, yet its stock has seen significant gains, up 37.34% in one month and 141.36% year-to-date. Despite trading at a price-to-book ratio of 8x, well above industry averages, and showing increasing losses, an SWS Discounted Cash Flow model suggests a large undervaluation. This discrepancy highlights investor focus on its pipeline and future potential, despite current unprofitability and risks associated with unproven clinical programs.